Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Radiology
Published in: European Radiology 5/2015

01-05-2015 | Nuclear Medicine

Improved dopamine transporter binding activity after bone marrow mesenchymal stem cell transplantation in a rat model of Parkinson’s disease: small animal positron emission tomography study with F-18 FP-CIT

Authors: Bok-Nam Park, Jang-Hee Kim, Kwanjae Lee, So Hyun Park, Young-Sil An

Published in: European Radiology | Issue 5/2015

Login to get access

Abstract

Objectives

We evaluated the effects of bone marrow-derived mesenchymal stem cells (BMSCs) in a model of Parkinson’s disease (PD) using serial F-18 fluoropropylcarbomethoxyiodophenylnortropane (FP-CIT) PET.

Methods

Hemiparkinsonian rats were treated with intravenously injected BMSCs, and animals without stem cell therapy were used as the controls. Serial FP-CIT PET was performed after therapy. The ratio of FP-CIT uptake in the lesion side to uptake in the normal side was measured. The changes in FP-CIT uptake were also analyzed using SPM. Behavioural and histological changes were observed using the rotational test and tyrosine hydroxylase (TH)-reactive cells.

Results

FP-CIT uptake ratio was significantly different in the BMSCs treated group (n = 28) at each time point. In contrast, there was no difference in the ratio in control rats (n = 25) at any time point. SPM analysis also revealed that dopamine transporter binding activity was enhanced in the right basal ganglia area in only the BMSC therapy group. In addition, rats that received BMSC therapy also exhibited significantly improved rotational behaviour and preservation of TH-positive neurons compared to controls.

Conclusions

The therapeutic effect of intravenously injected BMSCs in a rat model of PD was confirmed by dopamine transporter PET imaging, rotational functional studies, and histopathological evaluation.

Key Points

• Mesenchymal stem cells were intravenously injected to treat the PD rats
• Dopamine transporter binding activity was improved after stem cell therapy
• Stem cell therapy induced functional recovery and preservation of dopaminergic neurons
• The effect of stem cells was confirmed by FP-CIT PET
Literature
1.
Beitz JM (2014) Parkinson’s disease: a review. Front Biosci (Schol Ed) 6:65–74CrossRef
2.
Toulouse A, Sullivan AM (2008) Progress in Parkinson’s disease-where do we stand? Prog Neurobiol 85:376–392CrossRefPubMed
3.
Glavaski-Joksimovic A, Bohn MC (2013) Mesenchymal stem cells and neuroregeneration in Parkinson’s disease. Exp Neurol 247:25–38CrossRefPubMed
4.
Ali F, Stott SR, Barker RA (2014) Stem cells and the treatment of Parkinson’s disease. Exp Neurol 260:3–11CrossRefPubMed
5.
Yang M, Donaldson AE, Jiang Y, Iacovitti L (2003) Factors influencing the differentiation of dopaminergic traits in transplanted neural stem cells. Cell Mol Neurobiol 23:851–864CrossRefPubMedCentralPubMed
6.
Bjorklund LM, Sanchez-Pernaute R, Chung S et al (2002) Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc Natl Acad Sci U S A 99:2344–2349CrossRefPubMedCentralPubMed
7.
Bouchez G, Sensebe L, Vourc’h P et al (2008) Partial recovery of dopaminergic pathway after graft of adult mesenchymal stem cells in a rat model of Parkinson’s disease. Neurochem Int 52:1332–1342CrossRefPubMed
8.
Clarkson ED (2001) Fetal tissue transplantation for patients with Parkinson’s disease: a database of published clinical results. Drugs Aging 18:773–785CrossRefPubMed
9.
Wang F, Yasuhara T, Shingo T et al (2010) Intravenous administration of mesenchymal stem cells exerts therapeutic effects on parkinsonian model of rats: focusing on neuroprotective effects of stromal cell-derived factor-1alpha. BMC Neurosci 11:52CrossRefPubMedCentralPubMed
10.
Pittenger MF, Mackay AM, Beck SC et al (1999) Multilineage potential of adult human mesenchymal stem cells. Sci 284:143–147CrossRef
11.
Venkataramana NK, Kumar SK, Balaraju S et al (2010) Open-labeled study of unilateral autologous bone-marrow-derived mesenchymal stem cell transplantation in Parkinson’s disease. Transl Res 155:62–70CrossRefPubMed
12.
Danielyan L, Schafer R, von Ameln-Mayerhofer A et al (2011) Therapeutic efficacy of intranasally delivered mesenchymal stem cells in a rat model of Parkinson disease. Rejuvenation Res 14:3–16CrossRefPubMed
13.
Xiong N, Zhang Z, Huang J et al (2011) VEGF-expressing human umbilical cord mesenchymal stem cells, an improved therapy strategy for Parkinson’s disease. Gene Ther 18:394–402CrossRefPubMed
14.
Scherfler C, Donnemiller E, Schocke M et al (2002) Evaluation of striatal dopamine transporter function in rats by in vivo beta-[123I]CIT pinhole SPECT. Neuroimage 17:128–141CrossRefPubMed
15.
Booij J, Speelman JD, Horstink MW, Wolters EC (2001) The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. Eur J Nucl Med 28:266–272CrossRefPubMed
16.
Winogrodzka A, Bergmans P, Booij J, van Royen EA, Janssen AG, Wolters EC (2001) [123I]FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson’s disease. J Neural Transm 108:1011–1019CrossRefPubMed
17.
Nakano Y, Hirko AC, Smith AD et al (2004) Presynaptic dopaminergic properties of differentiated mouse embryonic stem cells. Neurochem Int 45:1067–1073CrossRefPubMed
18.
Kyono K, Takashima T, Katayama Y et al (2011) Use of [18F]FDOPA-PET for in vivo evaluation of dopaminergic dysfunction in unilaterally 6-OHDA-lesioned rats. EJNMMI Res 1:25CrossRefPubMedCentralPubMed
19.
Mahmood A, Lu D, Chopp M (2004) Intravenous administration of marrow stromal cells (MSCs) increases the expression of growth factors in rat brain after traumatic brain injury. J Neurotrauma 21:33–39CrossRefPubMed
20.
Gutierrez-Fernandez M, Rodriguez-Frutos B, Ramos-Cejudo J et al (2013) Effects of intravenous administration of allogenic bone marrow- and adipose tissue-derived mesenchymal stem cells on functional recovery and brain repair markers in experimental ischemic stroke. Stem Cell Res Ther 4:11CrossRefPubMedCentralPubMed
21.
Casteels C, Vermaelen P, Nuyts J et al (2006) Construction and evaluation of multitracer small-animal PET probabilistic atlases for voxel-based functional mapping of the rat brain. J Nucl Med 47:1858–1866PubMed
22.
Nie B, Chen K, Zhao S et al (2013) A rat brain MRI template with digital stereotaxic atlas of fine anatomical delineations in paxinos space and its automated application in voxel-wise analysis. Hum Brain Mapp 34:1306–1318CrossRefPubMedCentralPubMed
23.
Dabbeni-Sala F, Di Santo S, Franceschini D, Skaper SD, Giusti P (2001) Melatonin protects against 6-OHDA-induced neurotoxicity in rats: a role for mitochondrial complex I activity. FASEB J 15:164–170CrossRefPubMed
24.
Nagatsu T, Levitt M, Udenfriend S (1964) Tyrosine hydroxylase. The initial step in norepinephrine biosynthesis. J Biol Chem 239:2910–2917PubMed
25.
Alvarez-Fischer D, Blessmann G, Trosowski C et al (2007) Quantitative [(123)I]FP-CIT pinhole SPECT imaging predicts striatal dopamine levels, but not number of nigral neurons in different mouse models of Parkinson’s disease. Neuroimage 38:5–12CrossRefPubMed
26.
27.
28.
McLarty K, Reilly RM (2007) Molecular imaging as a tool for personalized and targeted anticancer therapy. Clin Pharmacol Ther 81:420–424CrossRefPubMed
29.
Nurmi E, Ruottinen HM, Bergman J et al (2001) Rate of progression in Parkinson’s disease: a 6-[18F]fluoro-L-dopa PET study. Mov Disord 16:608–615CrossRefPubMed
30.
Ungerstedt U (1971) Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol Scand Suppl 367:69–93CrossRefPubMed
31.
Kawasaki H, Mizuseki K, Nishikawa S et al (2000) Induction of midbrain dopaminergic neurons from ES cells by stromal cell-derived inducing activity. Neuron 28:31–40CrossRefPubMed
32.
Brederlau A, Correia AS, Anisimov SV et al (2006) Transplantation of human embryonic stem cell-derived cells to a rat model of Parkinson’s disease: effect of in vitro differentiation on graft survival and teratoma formation. Stem Cells 24:1433–1440CrossRefPubMed
33.
Kim JH, Auerbach JM, Rodriguez-Gomez JA et al (2002) Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson’s disease. Nat 418:50–56CrossRef
34.
Li Y, Chen J, Wang L, Zhang L, Lu M, Chopp M (2001) Intracerebral transplantation of bone marrow stromal cells in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease. Neurosci Lett 316:67–70CrossRefPubMed
35.
Hellmann MA, Panet H, Barhum Y, Melamed E, Offen D (2006) Increased survival and migration of engrafted mesenchymal bone marrow stem cells in 6-hydroxydopamine-lesioned rodents. Neurosci Lett 395:124–128CrossRefPubMed
36.
Park HJ, Lee PH, Bang OY, Lee G, Ahn YH (2008) Mesenchymal stem cells therapy exerts neuroprotection in a progressive animal model of Parkinson’s disease. J Neurochem 107:141–151CrossRefPubMed
37.
Fu YS, Cheng YC, Lin MY et al (2006) Conversion of human umbilical cord mesenchymal stem cells in Wharton’s jelly to dopaminergic neurons in vitro: potential therapeutic application for Parkinsonism. Stem Cells 24:115–124CrossRefPubMed
38.
Khoo ML, Tao H, Meedeniya AC, Mackay-Sim A, Ma DD (2011) Transplantation of neuronal-primed human bone marrow mesenchymal stem cells in hemiparkinsonian rodents. PLoS One 6:e19025CrossRefPubMedCentralPubMed
39.
Phinney DG, Prockop DJ (2007) Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair–current views. Stem Cells 25:2896–2902CrossRefPubMed
40.
Blandini F, Cova L, Armentero MT et al (2010) Transplantation of undifferentiated human mesenchymal stem cells protects against 6-hydroxydopamine neurotoxicity in the rat. Cell Transplant 19:203–217CrossRefPubMed
41.
Aizman I, Tate CC, McGrogan M, Case CC (2009) Extracellular matrix produced by bone marrow stromal cells and by their derivative, SB623 cells, supports neural cell growth. J Neurosci Res 87:3198–3206CrossRefPubMed
42.
Kozlowska H, Jablonka J, Janowski M, Jurga M, Kossut M, Domanska-Janik K (2007) Transplantation of a novel human cord blood-derived neural-like stem cell line in a rat model of cortical infarct. Stem Cells Dev 16:481–488CrossRefPubMed
43.
Kraitchman DL, Tatsumi M, Gilson WD et al (2005) Dynamic imaging of allogeneic mesenchymal stem cells trafficking to myocardial infarction. Circ 112:1451–1461CrossRef
44.
Yoon JK, Park BN, Shim WY, Shin JY, Lee G, Ahn YH (2010) In vivo tracking of 111In-labeled bone marrow mesenchymal stem cells in acute brain trauma model. Nucl Med Biol 37:381–388CrossRefPubMed
45.
Gleave JA, Farncombe TH, Saab C, Doering LC (2011) Correlative single photon emission computed tomography imaging of [123I]altropane binding in the rat model of Parkinson’s. Nucl Med Biol 38:741–749CrossRefPubMed
Metadata
Title
Improved dopamine transporter binding activity after bone marrow mesenchymal stem cell transplantation in a rat model of Parkinson’s disease: small animal positron emission tomography study with F-18 FP-CIT
Authors
Bok-Nam Park
Jang-Hee Kim
Kwanjae Lee
So Hyun Park
Young-Sil An
Publication date
01-05-2015
Publisher
Springer Berlin Heidelberg
Published in
European Radiology / Issue 5/2015
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-014-3549-3

Other articles of this Issue 5/2015

European Radiology 5/2015 Go to the issue

Head and Neck

Radiation dose and image quality of 70 kVp cerebral CT angiography with optimized sinogram-affirmed iterative reconstruction: comparison with 120 kVp cerebral CT angiography

Head and Neck

MRI in the evaluation of facial dermal fillers in normal and complicated cases

Musculoskeletal

Ultrasound-guided percutaneous injection to treat de Quervain’s disease using three different techniques: a randomized controlled trial

Urogenital

Molecular imaging of prostate cancer: translating molecular biology approaches into the clinical realm

Forensic Medicine

Diffusion-weighted perinatal postmortem magnetic resonance imaging as a marker of postmortem interval

Computed Tomography

Dual energy computed tomography quantification of carotid plaques calcification: comparison between monochromatic and polychromatic energies with pathology correlation